Replies to post #120119 on Biotech Values

[DewDiligence]

EMIS never fully recovered from its disastrous phase-2 oral-insulin trial in India and the disingenuous way in which it presented the results (#msg-14395914, #msg-14397293).

[investorgold2002]

EMIS has huge dilution risk.

I was very interested in it's oral calcitonin for OP and OA.
OP seems like a sure deal. In fact Novartis has in its pipeline for NDA in 2011. It is in pivotal phase 3 trial

OA is very interesting in that it can be approved as "disease modifying" indication provided phase 3 suceeds. Ofcourse this is a bit speculative, but OP one looks like has a great chance...see my dd in yahoo.finance


Beside being low on cash,it has one huge corp governance issue. There is one majority shareholder(fund manager) who has provided loans and there is huge risk that this guy will steal all of public shares. They hardly does ANY PR. Management of this company hardly have any incentives in terms of stock. Nobody knows about this stock. I am sure this guy(majority shareholder) is running stuff behind the scenes.He and his cronies are in the board. they keep hiring new ceos. Look at my postings from a year back on this.
This is the major reason I walked away from this investment after following this for 3-4 months.

[DewDiligence]

EMIS off 30% as NVS dumps oral PTH program:

http://finance.yahoo.com/news/Emisphere-Receives-Notice-of-pz-1668969247.html?x=0&.v=1

Novartis informed Emisphere that, although the study confirmed that oral PTH1-34 was both safe and well-tolerated, several clinical endpoints were not met. Based on the data analyzed, Novartis has terminated the study and anticipates no further work on the oral formulation of PTH1-34.

EMIS is one of those biotech companies that never seems to get anything right. The company is still reeling from the debacle with oral insulin five years ago (#msg-14395914, #msg-14397293) and has never been adequately capitalized.